Peptide
    Prescription Required

    Tesamorelin

    FDA-Approved Growth Hormone Releasing Peptide

    The only FDA-approved GHRH analog for reducing visceral adipose tissue, with proven benefits for body composition and metabolic health.

    Visceral fat reductionImproved body compositionEnhanced GH levelsMetabolic health support

    About Tesamorelin

    Tesamorelin (brand name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog that has gained FDA approval for the treatment of HIV-associated lipodystrophy. Unlike many other peptides, Tesamorelin has undergone rigorous clinical trials and is prescribed by physicians for its proven ability to reduce visceral adipose tissue (VAT)—the dangerous fat that surrounds internal organs. Research has shown it can reduce trunk fat by up to 18% while preserving subcutaneous fat and lean muscle mass. Tesamorelin works by stimulating the pituitary gland to produce and release natural growth hormone, making it a preferred option for those seeking the benefits of optimized GH levels through a medically-supervised approach.

    Mechanism of Action

    Tesamorelin is a 44-amino acid synthetic peptide analog of human growth hormone-releasing hormone (GHRH). It binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. This mechanism preserves the body's natural feedback regulation, resulting in physiological GH pulses rather than constant elevation. The increased GH then promotes lipolysis (fat breakdown), particularly in visceral adipose tissue, while supporting lean tissue maintenance.

    How Tesamorelin Works in Your Body:

    • Target Receptors: Tesamorelin binds to specific receptors that trigger downstream signaling cascades related to its primary benefits.
    • Physiological Response: The body responds by modulating natural processes—whether hormone release, tissue repair, or cellular signaling—without replacing endogenous function.
    • Timeline: Effects typically begin within a few days, with optimal results seen over the recommended protocol duration.

    Dosing Protocol

    Frequency

    Once daily

    Timing

    Before bed or in the morning on empty stomach

    Duration

    Ongoing with physician supervision

    Important Notes

    Subcutaneous injection. Prescription required. Regular monitoring of IGF-1 levels recommended.

    Clinical Research

    3 studies on Tesamorelin

    Study #01

    Visceral Adipose Tissue Reduction

    Tesamorelin reduced trunk fat by 15-18% in HIV patients with lipodystrophy over 26 weeks, with maintained effects during continued treatment.

    New England Journal of Medicine

    Study #02

    Cardiovascular Risk Markers

    Treatment improved triglyceride levels and other cardiovascular risk markers in patients with excess visceral fat.

    Journal of Clinical Endocrinology & Metabolism

    Study #03

    Cognitive Function in Aging

    Preliminary studies suggest potential cognitive benefits in older adults, with improvements in executive function and verbal memory.

    Archives of Neurology

    GH Peptide Comparison

    Growth Hormone Peptides Compared

    Compare mechanism of action, FDA status, and use cases for the most popular growth hormone releasing peptides.

    Tesamorelin

    FDA-Approved GHRH Analog

    FDA Approved

    GH Release

    strong

    Side Effects

    moderate

    Primary Uses

    Visceral fat reduction
    Body composition
    Metabolic health

    Those seeking FDA-approved option for visceral fat reduction with physician oversight

    Learn More

    Sermorelin

    The Gold Standard GHRH

    Compounded

    GH Release

    moderate

    Side Effects

    minimal

    Primary Uses

    Anti-aging
    Sleep quality
    Recovery
    Muscle preservation

    Beginners seeking gentle GH optimization with excellent safety profile

    Learn More

    CJC-1295

    Extended-Release GHRH

    Research

    GH Release

    strong

    Side Effects

    moderate

    Primary Uses

    Sustained GH elevation
    Muscle growth
    Fat loss

    Those wanting less frequent dosing with sustained GH benefits

    Learn More

    Ipamorelin

    Clean GH Secretagogue

    Research

    GH Release

    moderate

    Side Effects

    minimal

    Primary Uses

    Fat loss
    Skin quality
    Energy
    Anti-aging

    Those wanting clean GH elevation without hormonal disruption

    Learn More

    FDA-Approved Option

    Tesamorelin is the only FDA-approved GHRH analog, offering the highest level of regulatory oversight for visceral fat reduction.

    Beginner-Friendly

    Sermorelin and Ipamorelin offer excellent tolerability profiles, making them ideal starting points for GH optimization.

    Synergistic Stacking

    GHRH peptides (Sermorelin, CJC-1295) can be stacked with GHRPs (Ipamorelin) for enhanced, synergistic GH release.

    Potential Side Effects

    • Injection site reactions
    • Joint pain (arthralgia)
    • Peripheral edema
    • Paresthesia (tingling)
    • Potential effect on glucose metabolism

    Stacks Well With

    Combining peptides can create synergistic effects. Learn about optimal timing, dosing, and protocols.

    Frequently Asked Questions About Tesamorelin

    Is Tesamorelin FDA approved?
    Yes. Tesamorelin (brand name Egrifta) is the only FDA-approved GHRH analog. It was approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it the most rigorously studied GH-releasing peptide available.
    How much visceral fat can Tesamorelin reduce?
    Clinical trials published in the New England Journal of Medicine showed Tesamorelin reduced trunk fat by 15-18% over 26 weeks, with effects maintained during continued treatment. It specifically targets visceral adipose tissue while preserving subcutaneous fat and lean muscle.
    What is the difference between Tesamorelin and Sermorelin?
    Both are GHRH analogs, but Tesamorelin is a full 44-amino acid peptide with FDA approval and stronger clinical evidence, particularly for visceral fat reduction. Sermorelin uses only the first 29 amino acids of GHRH and is available through compounding pharmacies. Tesamorelin generally produces a stronger GH response.

    Learn More About Tesamorelin

    Explore our research library and educational resources to understand how Tesamorelin can support your health goals.